Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNA HPV therapeutic vaccine
- Development stage
- Preclinical
- Lead developer
- Flashpoint Therapeutics
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Injection
01
Overview
The SNA HPV therapeutic vaccine is a spherical nucleic acid (SNA)-based nanovaccine developed by Flashpoint Therapeutics in collaboration with Northwestern University. It is designed as a therapeutic intervention for established HPV-driven cancers, including cervical and head and neck cancers. The vaccine utilizes a structural nanomedicine approach, where a nanoscale lipid core is surrounded by a globular shell of immune-activating CpG DNA (adjuvant) and HPV16 E7-derived peptide antigens (specifically E7₁₁₋₁₉). This unique architecture ensures the co-delivery of antigen and adjuvant to the same immune cells, optimizing the activation of CD8+ 'killer' T cells to recognize and destroy tumor cells expressing the HPV E7 oncoprotein. Preclinical data published in 2026 demonstrated significant tumor growth inhibition and improved survival in humanized models.
- Other names
- SNA-based HPV vaccinestructural nanomedicine HPV vaccine
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)TLR9 (Toll-like receptor 9)E7 (Papillomavirus E6/E7 oncoproteins)
Beyond the preview
Go deeper on SNA HPV therapeutic vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNA HPV therapeutic vaccine.